Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

121. Fam-trastuzumab deruxtecan-nxki (Enhertu) - metastatic breast cancer

Fam-trastuzumab deruxtecan-nxki (Enhertu) - metastatic breast cancer Drug Approval Package: ENHERTU ENHERTU " /> U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: ENHERTU Company: Daiichi Sankyo, Inc. Application Number: 761139 Approval Date: 12/20/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF

2020 FDA - Drug Approval Package

122. Enfortumab vedotin-ejfv (Padcev) - refractory bladder cancer

Enfortumab vedotin-ejfv (Padcev) - refractory bladder cancer Drug Approval Package: PADCEV enfortumab vedotin-ejfv U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: PADCEV enfortumab vedotin-ejfv Company: Astellas Pharma US, Inc. Application Number: 761137 Approval Date: 12/08/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application

2020 FDA - Drug Approval Package

123. Keratinocyte cancer (basal cell carcinoma and cutaneous squamous cell carcinoma)

Keratinocyte cancer (basal cell carcinoma and cutaneous squamous cell carcinoma) Clinical practice guidelines for keratinocyte cancer - Clinical Guidelines Wiki Skip Links Personal tools Search Navigation Cancer Council guidelines Bowel cancer Lung cancer Prostate cancer Skin cancer Methodology Hosted cancer guidelines Adolescents and Young Adult (AYA) guidelines Prevention Policies Social links Page actions The guideline recommendations were approved by the Chief Executive Officer (...) , and developed for health professionals practising in an Australian health care setting. This publication reflects the views of the authors and not necessarily the views of the Australian Government. Cite this guideline Cancer Council Australia Keratinocyte Cancers Guideline Working Party. Clinical practice guidelines for keratinocyte cancer. Sydney: Cancer Council Australia. [Version URL: , cited 2020 Feb 19]. Available from: . Please also see the following files: This is a wiki-based guideline. A PDF

2020 Cancer Council Australia

124. Therapy for Stage IV Non-Small Cell Lung Cancer without Driver Alterations

in epidermal growth factor receptor or ALK. For patients with high programmed death ligand 1 (PD-L1) expression (tumor proportion score [TPS] ≥ 50%) and non–squamous cell carcinoma (non-SCC), the Expert Panel recommends single-agent pembrolizumab. Additional treatment options include pembrolizumab/carboplatin/pemetrexed, atezolizumab/carboplatin/paclitaxel/bevacizumab, or atezolizumab/carboplatin/nab-paclitaxel. For most patients with non-SCC and either negative (0%) or low positive (1% to 49%) PD-L1 (...) Guideline Update Guideline Question What systemic therapy treatment options should be offered to patients with stage IV non–small-cell lung cancer (NSCLC) without driver alterations, depending on the subtype of the patient’s cancer? Target Population Patients with stage IV NSCLC without driver alterations in epidermal growth factor receptor ( EGFR ) or anaplastic lymphoma kinase ( ALK ) (with known EGFR and ALK ) status (plus programmed death ligand 1 (PD-L1) tumor proportion score (TPS) test results

2020 American Society of Clinical Oncology Guidelines

125. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer

and could be considered for inclusion in the evidence base. As a second stage, the focus was on locating and evaluating primary literature not already covered in any existing systematic reviews. PubMed was used to systematically search for articles evaluating the clinical utility of germline and somatic tumor testing in ovarian cancer, again between 2007 and March 23, 2018. The search combined disease-specific terms (neoplasm, carcinoma, cancer) along with site-specific terms (ovary, ovarian) and gene (...) status determined using the Myriad Genetics myChoice CDx as either tumor BRCA mutated and/or a genomic instability score ≥ 42. Patients with HRD-positive cancers but without BRCA mutations must have experienced progression at least 6 months after the last dose of platinum-based therapy (ie, must have platinum-sensitive disease). The value of testing for the mismatch repair (MMR) phenotype is the tissue-agnostic FDA approval of pembrolizumab for patients with microsatellite instability–high (MSI-H

2020 American Society of Clinical Oncology Guidelines

126. Dataset for histopathological reporting of gastrointestinal stromal tumours

infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res 2013;73:3499–3510. 29. Brierley J, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours (8th edition). Oxford, UK: Wiley-Blackwell, 2017. CEff 090120 16 V3 Final Appendix A SNOMED coding Topography Tumour site SNOMED 2/3 code SNOMED CT terminology SNOMED CT code Oesophagus T-62000/T-56000 Entire oesophagus (body structure) 181245004 Stomach T-63000/T-57000 Entire stomach (body structure) 181246003 (...) (body structure) 181262009 Peritoneum T-Y4400/T-D4400 Entire peritoneum (serous membrane) (body structure) 362698002 Omentum T-63850/T-D4600 Entire omentum (body structure) 362710002 Liver T-56000/T-62000 Entire liver (body structure) 181268008 Morphology Morphological codes SNOMED 2/3/ ICD-O code SNOMED CT terminology SNOMED CT code Gastrointestinal stromal tumour, malignant M89363 Gastrointestinal stromal sarcoma (morphologic abnormality) 128756002 Procedure Local P codes should be recorded

2020 British Society of Gastroenterology

127. Estrogen and Progesterone Receptor Testing in Breast Cancer Guideline Update

% to 10% staining. Similar principles apply to PgR testing, which is used primarily for prognostic purposes in the setting of an ER-positive cancer. Testing of ductal carcinoma in situ (DCIS) for ER is recommended to determine potential benefit of endocrine therapies to reduce risk of future breast cancer, while testing DCIS for PgR is considered optional. Additional information can be found at www.asco.org/breast-cancer-guidelines. (ArchPatholLabMed.doi:10.5858/arpa.2019-0904-SA) INTRODUCTION F irst (...) tested for hormone receptors? Target Population Patients with breast cancer. Target Audience Medical oncologists, pathologists, surgeons, radiation oncologists, and patients and their caregivers. Methods A multidisciplinary Expert Panel was convened to update the clinical practice guideline recommendations based on a systematic review of the medical literature. Recommendations Recommendation 1.1: Optimal algorithm for ER/progesterone receptor testing. Samples with 1% to 100% of tumor nuclei positive

2020 College of American Pathologists

128. Bone Health and Bone-targeted Therapies for Prostate Cancer

for Prostate Cancer guideline. This guideline included recommendations across a relatively broad clinical spectrum within prostate cancer. Topics addressed ranged from management of osteoporotic fracture risk in nonmetastatic disease to management of men with castration-resistant prostate cancer metastatic to bone. ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. METHODS The Bone Health and Bone-Targeted (...) -targeted therapies for prostate cancer. The CCO practice recommendations are drawn from data provided by randomized controlled trials (RCT) and systematic reviews of bone-targeted therapies in men with prostate cancer in a variety of settings. Relevant clinical risks range from osteoporotic fractures associated with androgen-deprivation therapy (ADT) to morbidity and death as a result of progression of bone-metastatic castration-resistant disease. In this document, the ASCO Expert Panel (Appendix

2020 American Society of Clinical Oncology Guidelines

129. Estrogen and Progesterone Receptor Testing in Breast Cancer

with 1% to 100% of tumor nuclei positive should be interpreted as ER positive. However, the Expert Panel acknowledges that there are limited data on endocrine therapy benefit for cancers with 1% to 10% of cells staining ER positive. Samples with these results should be reported using a new reporting category, ER Low Positive, with a recommended comment. A sample is considered ER negative if < 1% or 0% of tumor cell nuclei are immunoreactive. Additional strategies recommended to promote optimal (...) performance, interpretation, and reporting of cases with an initial low to no ER staining result include establishing a laboratory-specific standard operating procedure describing additional steps used by the laboratory to confirm/adjudicate results. The status of controls should be reported for cases with 0% to 10% staining. Similar principles apply to PgR testing, which is used primarily for prognostic purposes in the setting of an ER-positive cancer. Testing of ductal carcinoma in situ (DCIS) for ER

2020 American Society of Clinical Oncology Guidelines

130. Testosterone replacement in young male cancer survivors: A 6-month double-blind randomised placebo-controlled trial Full Text available with Trip Pro

Testosterone replacement in young male cancer survivors: A 6-month double-blind randomised placebo-controlled trial Testosterone Replacement in Young Male Cancer Survivors: A 6-month Double-Blind Randomised Placebo-Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable (...) your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Randomized Controlled Trial PLoS Med Actions , 16 (11), e1002960 2019 Nov 12 eCollection Nov 2019 Testosterone Replacement in Young Male Cancer Survivors: A 6-month Double-Blind Randomised Placebo-Controlled Trial , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Oncology and Metabolism

2020 EvidenceUpdates

131. Cancer Screening: Interventions Engaging Community Health Workers – Breast Cancer

neoplasms/ or colonic neoplasms/ or rectal neoplasms/) and (di or pc).fs. 3. ((adenoma* or neoplasia or cancer* or neoplasm* or tumo?r* or carcinoma* or adenocarcinoma*) and (breast or cervical or cervix or colon or colorectal or crc)).ti,ab. 4. 2 or 3 5. 1 and 4 6. colonography, computed tomographic/ or colonoscopy/ or endoscopy, gastrointestinal/ or sigmoidoscopy/ or ((occult blood.ti,ab. or occult blood/) and (feces/ or (faeces or fecal or faecal or colorectal).ti,ab.)) or (enema/ and barium sulfate (...) or 42 CommGuideCancerMCIPsycINFO 1. (mass screening or multiphasic screening or screen or screened or screening or "early detection of cancer").mp. 2. ((neoplasm* or ductal breast carcinoma* or "hereditary breast and ovarian cancer syndrome") and (diagnosis or prevention)).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures] 3. ((adenoma* or neoplasia or cancer* or neoplasm* or tumo?r* or carcinoma* or adenocarcinoma*) and (breast or cervical

2020 Community Preventive Services Task Force

132. Cancer Screening: Interventions Engaging Community Health Workers – Cervical Cancer

/ or multiphasic screening/ or (screen or screened or screening).ti,ab. or "early detection of cancer"/ 2. (neoplasms/ or breast neoplasms/ or colorectal neoplasms/ or uterine cervical neoplasms/ or carcinoma, ductal, breast/ or "hereditary breast and ovarian cancer syndrome"/ or inflammatory breast neoplasms/ or colonic neoplasms/ or rectal neoplasms/) and (di or pc).fs. 3. ((adenoma* or neoplasia or cancer* or neoplasm* or tumo?r* or carcinoma* or adenocarcinoma*) and (breast or cervical or cervix or colon (...) * or "hereditary breast and ovarian cancer syndrome") and (diagnosis or prevention)).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures] 3. ((adenoma* or neoplasia or cancer* or neoplasm* or tumo?r* or carcinoma* or adenocarcinoma*) and (breast or cervical or cervix or colon or colorectal or crc)).mp. 4. 2 or 3 5. 1 and 4 6. ((colonography or colonoscopy or gastrointestinal endoscopy or sigmoidoscopy or occult blood) and (feces or faeces or fecal or faecal

2020 Community Preventive Services Task Force

133. Cancer Screening: Interventions Engaging Community Health Workers – Colorectal Cancer

or screening or "early detection of cancer").mp. 2. ((neoplasm* or ductal breast carcinoma* or "hereditary breast and ovarian cancer syndrome") and (diagnosis or prevention)).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures] 3. ((adenoma* or neoplasia or cancer* or neoplasm* or tumo?r* or carcinoma* or adenocarcinoma*) and (breast or cervical or cervix or colon or colorectal or crc)).mp. 4. 2 or 3 5. 1 and 4 6. ((colonography or colonoscopy (...) or screening).ti,ab. or "early detection of cancer"/ 20. (neoplasms/ or breast neoplasms/ or colorectal neoplasms/ or uterine cervical neoplasms/ or carcinoma, ductal, breast/ or "hereditary breast and ovarian cancer syndrome"/ or inflammatory breast neoplasms/ or colonic neoplasms/ or rectal neoplasms/) and (di or pc).fs. 21. ((adenoma* or neoplasia or cancer* or neoplasm* or tumo?r* or carcinoma* or adenocarcinoma*) and (breast or cervical or cervix or colon or colorectal or crc)).ti,ab. 22. 20 or 21 23

2020 Community Preventive Services Task Force

134. Management of Appendiceal Neoplasms

= peritoneal mucinous carcinomatosis; PMCA-S = peritoneal mucinous carcinomatosis with signet ring cells; PMP = pseudomyxoma peritonei.Copyright © The American Society of Colon & Rectal Surgeons, Inc. Unauthorized reproduction of this article is prohibited. DISEASES OF THE COLON & RECTUM VOLUME 62: 12 (2019) 1427 AND (adenocarcinoma, carcinoma, mucinous, pseudomyx- oma, signet*, cystadenoma, tumor*, tumour*, neoplasm, cancer). These groups were combined with various treat- ment modalities to include (...) . Final recommendations were approved by the ASCRS Executive Committee. In general, Primary search terms: (appendiceal OR appendix OR appendicular) AND (adenocarcinoma OR carcinoma OR mucinous OR pseudomyxoma OR signet* OR cystadenoma OR tumor* OR tumour* OR neoplasm* OR cancer*) AND (therapy OR treatment OR chemotherapy OR HIPEC OR immunotherapy OR antineoplastic OR surgery OR oncological procedure OR diagnosis) Databases: Ovid Medline, Embase, Scopus Years covered: January 1, 1997–April 30, 2019

2020 American Society of Colon and Rectal Surgeons

135. Effect of True and Sham Acupuncture on Radiation-Induced Xerostomia Among Patients With Head and Neck Cancer: A Randomized Clinical Trial Full Text available with Trip Pro

control (SCC) with true acupuncture (TA) and sham acupuncture (SA) among patients with oropharyngeal or nasopharyngeal carcinoma who were undergoing radiation therapy in comprehensive cancer centers in the United States and China. Patients were enrolled between December 16, 2011, and July 7, 2015. Final follow-up was August 15, 2016. Analyses were conducted February 1 through 28, 2019. Intervention: Either TA or SA using a validated acupuncture placebo device was performed 3 times per week during a 6 (...) Effect of True and Sham Acupuncture on Radiation-Induced Xerostomia Among Patients With Head and Neck Cancer: A Randomized Clinical Trial Effect of True and Sham Acupuncture on Radiation-Induced Xerostomia Among Patients With Head and Neck Cancer: A Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other

2020 EvidenceUpdates

136. Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01) Full Text available with Trip Pro

-01-20 ) DOI: Item in Clipboard Full-text links Cite Abstract Purpose: Operable triple-negative breast cancers (TNBCs) have a higher risk of relapse than non-TNBCs with standard therapy. The GEICAM/2003-11_CIBOMA/2004-01 trial explored extended adjuvant capecitabine after completion of standard chemotherapy in patients with early TNBC. Patients and methods: Eligible patients were those with operable, node-positive-or node negative with tumor 1 cm or greater-TNBC, with prior anthracycline (...) -95. 2015. PMID 26416999. - Clinical Trial Invasive disease-free survival, but not OS, was significantly superior for patients with node-positive early BC who received the adjuvant standard schedule EC-T than for … A Natori et al. Eur J Cancer 77, 40-47. May 2017. PMID 28355581. - Review Adding capecitabine to standard chemotherapy appears to improve DFS and OS in TNBC, but increases adverse events in keeping with its known toxicity profile. Y Jiang et al. PLoS One 7 (3), e32474. 2012. PMID

2020 EvidenceUpdates

137. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial (Abstract)

Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial Abiraterone acetate plus prednisone and enzalutamide are both used for the treatment of metastatic castration-resistant prostate cancer. We aimed to determine the best sequence in which to use both drugs, as well as their second-line efficacy.In this multicentre, randomised, open-label, phase 2, crossover (...) trial done in six cancer centres in British Columbia, Canada, we recruited patients aged 18 years or older with newly-diagnosed metastatic castration-resistant prostate cancer without neuroendocrine differentiation and Eastern Cooperative Oncology Group performance status 2 or less. Patients were randomly assigned (1:1) using a computer-generated random number table to receive either abiraterone acetate 1000 mg orally once daily plus prednisone 5 mg orally twice daily until PSA progression followed

2020 EvidenceUpdates

138. eUpdate: Hepatocellular Carcinoma Algorithms

Testicular Germ Cell CancerCancer of the Prostate • Bladder Cancer • Renal Cell Carcinoma • Penile Carcinoma • Testicular Seminoma and Non-Seminoma Gynaecological Cancers Cervical cancer • Endometrial cancer • Gestational trophoblastic disease • Newly diagnosed and relapsed epithelial ovarian carcinoma • Non-epithelial ovarian cancer • Ovarian Cancer Haematological Malignancies Waldenstrom's macroglobulinaemia • Chronic myeloid leukaemia • Newly diagnosed and relapsed mantle cell lymphoma • Multiple (...) marginal zone lymphoma of MALT type Head and Neck Cancers Nasopharyngeal Cancer • Squamous-Cell Carcinoma of the Head and Neck Hereditary Syndromes Prevention and Screening in BRCA Mutation Carriers and Other Breast/Ovarian Hereditary Cancer Syndromes Lung and Chest Tumours Early and locally advanced non-small-cell lung cancer • Metastatic non-small-cell lung cancer • Thymic epithelial tumoursMalignant pleural mesothelioma • Small-cell lung cancer Melanoma Cutaneous Melanoma Neuro-Oncology EANO

2020 European Society for Medical Oncology

139. eUpdate: Hepatocellular Carcinoma Treatment Recommendations

carcinoma Genitourinary Cancers Testicular Germ Cell CancerCancer of the Prostate • Bladder Cancer • Renal Cell Carcinoma • Penile Carcinoma • Testicular Seminoma and Non-Seminoma Gynaecological Cancers Cervical cancer • Endometrial cancer • Gestational trophoblastic disease • Newly diagnosed and relapsed epithelial ovarian carcinoma • Non-epithelial ovarian cancer • Ovarian Cancer Haematological Malignancies Waldenstrom's macroglobulinaemia • Chronic myeloid leukaemia • Newly diagnosed and relapsed (...) in adult patients • Gastric marginal zone lymphoma of MALT type Head and Neck Cancers Nasopharyngeal Cancer • Squamous-Cell Carcinoma of the Head and Neck Hereditary Syndromes Prevention and Screening in BRCA Mutation Carriers and Other Breast/Ovarian Hereditary Cancer Syndromes Lung and Chest Tumours Early and locally advanced non-small-cell lung cancer • Metastatic non-small-cell lung cancer • Thymic epithelial tumoursMalignant pleural mesothelioma • Small-cell lung cancer Melanoma Cutaneous

2020 European Society for Medical Oncology

140. Society of Interventional Radiology Position Statement on the Role of Percutaneous Ablation in Renal Cell Carcinoma. Full Text available with Trip Pro

Panel Formation Under the direction of SIR, a multidisciplinary group of experts, representing Interventional Radiology, Urology, and Interventional Oncology, was convened to review the current literature on the use of ablation for the management of RCC. Literature Review A comprehensive literature search was conducted in June 2019 in MEDLINE via PubMed using a combination of the following search terms: “renal cell carcinoma,” “renal tumors,” “RCC,” “metastatic renal cancer,” “oligometastatic (...) expenditures after local tumour ablation or partial nephrectomy for T1A kidney cancer. Eur J Surg Oncol . 2017 ; 43 : 815–822 | | | | | 32 ) determined that local tumor ablation is associated with lower overall complication rates (21% vs 40%; OR = 0.38, 95% CI, 0.28–0.5) and shorter median length of stay (2 days vs 4 days) than PN. Similarly, Talenfeld et al ( x 19 Talenfeld, A.D., Gennarelli, R.L., Elkin, E.B. et al. Percutaneous ablation versus partial and radical nephrectomy for T1a renal cancer

2020 Society of Interventional Radiology